NASDAQ$TCRX
Tscan Therapeutics Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
TScan Therapeutics reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.
TScan Therapeutics reported a revenue of $0.6 million and a net loss of $30.1 million for the first quarter of 2024. The company dosed the first patient in its Phase 1 solid tumor program and closed an upsized public offering with gross proceeds of $167.8 million, extending the company's cash runway into the fourth quarter of 2026.
- First patient dosed in Phase 1 clinical trial for the treatment of solid tumors; initial data anticipated in 2024.
- All treatment-arm patients in the Phase 1 heme program remain relapse-free with no detectable disease, with a median follow-up of >10 months.
- Closed upsized underwritten public offering with gross proceeds of $167.8 million, extending runway into the fourth quarter of 2026.
- The Company expects to complete Phase 1 enrollment and open expansion cohorts at the proposed recommended Phase 2 dose in the third quarter of 2024 and provide a data update near the end of 2024.
Headline financials
Revenue & EPS history
Tscan Therapeutics · Revenue · Quarterly
$566K
Revenue by segment
Tscan Therapeutics · $3.89M total across 1 segment · Q3 2023
- Collaboration & License$3.89M—100.0%
Forward guidance
TScan anticipates several milestones for its Heme Malignancies Program and Solid Tumor Program.
Tailwinds
- Opening of expansion cohorts at the proposed recommended Phase 2 dose level to further characterize safety and evaluate translational and efficacy endpoints is planned for the third quarter of 2024.
- Completion of Phase 1 enrollment and reporting of one-year clinical and translational data on initial patients is anticipated in the second half of 2024.
- Expects to initiate registration trial pending feedback from regulatory authorities and report two-year clinical and translational data in 2025.
- Phase 1 solid tumor clinical study has been initiated; first patient dosed in early May, with three additional patients enrolled and manufacturing underway.
- Initial data expected in the second half of 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2024
+1.6%
Avg return
Earnings day
+0.2%
Avg return
5 days after
-5.7%
Avg return
30 days after
60%
12 / 20 earnings
Positive
+32.4%
Q1 2023
Best reaction
-18.2%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.3% | -3.3% | -18.9% | |
| Q4 2025 | +4.9% | +19.8% | -2.4% | |
| Q3 2025 | +0.8% | -20.5% | -17.2% | |
| Q2 2025 | +3.1% | +11.8% | +14.9% | |
| Q1 2025 | -4.6% | +0.8% | +18.3% | |
| Q4 2024 | +2.6% | +7.7% | -7.1% | |
| Q3 2024 | -7.9% | -22.6% | -47.0% | |
| Q2 2024 | -1.0% | -3.0% | -3.9% | |
| Q1 2024 | +16.3% | +16.2% | +14.9% | |
| Q4 2023 | +1.6% | -6.7% | +0.9% | |
| Q3 2023 | +3.0% | +14.9% | +50.8% | |
| Q2 2023 | -4.2% | -2.3% | +12.1% | |
| Q1 2023 | +32.4% | +18.5% | -14.4% | |
| Q4 2022 | -8.5% | -23.0% | -33.3% | |
| Q3 2022 | -0.4% | +3.9% | -20.6% | |
| Q2 2022 | -10.8% | -18.8% | -20.5% | |
| Q1 2022 | +10.6% | +38.3% | +80.0% | |
| Q4 2021 | +7.8% | -1.6% | -37.8% | |
| Q3 2021 | +2.2% | -4.4% | -28.0% | |
| Q2 2021 | -18.2% | -21.7% | -53.7% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro